Exciting growth stocks are highly coveted, but some fly under the radar for various reasons. And this gives astute investors the opportunity to pounce before their shares rise significantly.

Mid-cap biotechs Madrigal Pharmaceuticals (NASDAQ: MDGL) and Axsome Therapeutics (NASDAQ: AXSM) seem to fit the bill. Both drugmakers look highly promising, and there could be plenty of upside at their current market values. Let's find out more.

Madrigal Pharmaceuticals recently earned approval from the U.S. Food and Drug Administration (FDA) for Rezdiffra, the first therapy on the market for non-alcoholic steatohepatitis (NASH), a severe liver disease affecting about 5% of adults in the U.S., according to some estimates.

Continue reading

Source Fool.com